# A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

> **NCT02363946** · PHASE1 · TERMINATED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 65 (actual)

## Conditions studied

- Alpha-1 Antitrypsin Deficiency

## Interventions

- **DRUG:** ARC-AAT Injection
- **OTHER:** Placebo
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT02363946
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** Company decision to terminate the trial
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02363946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02363946, "A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02363946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*